drugset
drugset / Trial / NCT07339553

Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.

NCT07339553 ↗

Phase 2 Not yet recruiting 30 enrolled Peking University Third Hospital
NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the efficacy and safety of Zeprumetostat in combination with Fuzuloparib for the treatment of patients with advanced or recurrent ovarian epithelial carcinoma, with the primary endpoint being Objective Response Rate (ORR).

Timeline

Start
2026-01-04
Primary completion
2029-01-30
Completion
2029-02-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluzoparib Small molecule 100 mg Oral
Subject Zeprumetostat Small molecule 250 mg Oral

Indications

ovarian carcinoma